AI Article Synopsis
- The study aimed to assess how common dyslipidemia (abnormal lipid levels) is among HIV patients undergoing highly active antiretroviral therapy (HAART) in a public hospital in Peru.
- After analyzing 2,975 clinical histories, 538 patients were included, revealing a high dyslipidemia prevalence of 74.7%.
- Findings indicated that using protease inhibitors and being over 40 years old increased the risk of dyslipidemia, highlighting the need for better monitoring and control of lipid levels in HIV care.
Article Abstract
The objective of the study was to determine the frequency and characteristics of dyslipidemia in patients with HIV in highly active antiretroviral therapy (HAART) in a Peruvian public hospital. A cross-sectional study was carried out in patients with complete lipid profile after receiving at least six months of HAART. Dyslipidemia was defined according to the criteria of the NCEP-ATP III. We reviewed 2 975 clinical histories, and included 538 (18.1%) in the analysis. The frequency of dyslipidemia was 74.7%. HAART regimens which include protease inhibitors (PI) (odds ratio [OR]: 1.22; confidence interval at 95% [CI 95%]: 1.11-1.33) and to be older than 40 years (OR: 1.17; CI 95%: 1.05-1.28) were associated with dyslipidemia, adjusted by viral load, CD4 lymphocyte level and gender. In conclusion, dyslipidemia was very common in our sample and was mainly associated with the use of PI. It is necessary to promote the dyslipidemia control as part of the comprehensive care of the patient with HIV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17843/rpmesp.2017.342.2587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!